Patent application number | Description | Published |
20080206241 | Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist - The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of chronic inflammatory disease, such as rheumatoid arthritis. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, and an anti-folate compounds, e.g., methotrexate, to a patient that has RA and pharmaceutical compositions comprising such antagonists. | 08-28-2008 |
20080286272 | EphA3 Antibodies for the Treatment of Solid Tumors - The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors. | 11-20-2008 |
20090136980 | CD10-activated prodrug compounds - The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing the prodrug are also disclosed. | 05-28-2009 |
20090191186 | Antibodies to the PcrV Antigen of Pseudomonas aeruginosa - The current invention provides high-affinity antibodies to the | 07-30-2009 |
20090263387 | Neutralization of GM-CSF for the Treatment of Heart Failure - This invention relates to methods of treating a patient suffering from heart failure, or a patient at risk for heart failure, using a GM-CSF antagonist. | 10-22-2009 |
20090274706 | ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR - The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies. | 11-05-2009 |
20100104569 | HUMANIZED ANTIBODIES TO INTERFERON ALPHA RECEPTOR-1 (IFNAR-1) - Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies. | 04-29-2010 |
20110086422 | HUMANIZED ANTIBODIES TO INTERFERON ALPHA RECEPTOR-1 (IFNAR-1) - Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies. | 04-14-2011 |
20110123549 | Antibodies to EphA3 - The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies. | 05-26-2011 |
20110165158 | METHODS FOR THE THERAPY OF INFLAMMATORY BOWEL DISEASE USING A TYPE-1 INTERFERON ANTAGONIST - Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR). | 07-07-2011 |
20120020986 | Antibodies to the PcrV Antigen of Pseudomonas aeruginosa - The current invention provides high-affinity antibodies to the | 01-26-2012 |
20120213776 | ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR - The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies. | 08-23-2012 |
20120309055 | Secretion of antibodies without signal peptides from bacteria - The present invention is directed generally to compositions and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from prokaryotes without the need for a signal peptide through making use of mutant host strains with altered secretory properties. In particular, the invention provides host cells and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from bacteria without the need for a signal peptide and provides diverse libraries of antibody sequence resulting from such methods. The invention additionally provides diverse libraries. | 12-06-2012 |
20140120114 | Antibodies to EphA3 - The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies. | 05-01-2014 |
20150030614 | ANTIBODIES TO THE PCRV ANTIGEN OF PSEUDOMONAS AERUGINOSA - The current invention provides high-affinity antibodies to the | 01-29-2015 |